The research objectives were to: 1) determine differences in BPSD based on clinical AD status (i.e., cognitively stable, MCI, and dementia); and 2) examine the association between neuroimaging biomarkers of early AD pathology (i.e., Aβ PET and tau PET) and BPSD in individuals with DS. This evidence concerns the gene MAPT and Dravet syndrome.